SYNE1基因启动子甲基化对大肠癌早期诊断的价值

Significance of SYNE1 promoter CpG island DNA methylation in early diagnosis of colorectal cancer

目的评价SYNE1基因启动子CpG岛甲基化在大肠癌早期诊断的潜在价值。方法采用甲基化特异性聚合酶链反应检测94例大肠癌组织(A组)及其癌旁正常组织(B组)和26例大肠腺瘤组织(C组)中SYNE1基因启动子CpG岛甲基化水平,分析其与大肠癌临床病理资料的关联。结果 A组SYNE1甲基化阳性率80.9%,高于B组的17.0%和C组的23.1%(P<0.01)。Ⅰ期大肠癌组织SYNE1基因甲基化阳性率66.7%(8/12),高于中低级腺瘤的6.7%(1/15)(P<0.01)。SYNE1基因甲基化水平与大肠癌临床病理特征之间无显著相关性(P>0.05)。结论 SYNE1基因甲基化是大肠癌发生的早期基因事件,SYNE1基因是大肠癌早期诊断的候选基因。

Objective To evaluate the value of SYNE1 promoter CpG island DNA methylation in early diagnosis of colorectal cancer. Methods Methylation specific polymerase chain reaction was used to determine the methylation status of SYNE1 in 94 colorectal cancer samples（group A）, tumor- adjacent normal tissues（group B） and 26 colorectal adenoma samples （group C）. The association of SYNE1 methylation and clinicopathological features was analyzed. Results The positive rate of SYNE1 methylation was higher in group A than that in groups of B and C（80.9% vs. 17.0% and 23.1%） （P〈0. 01）. The positive rate of SYNE1 methylation was higher in colorectal cancer Stage I than that in middle and low grade adenoma [66.7%（8/12） vs. 6.7%（1/15）]（P〈0. 01）. The level of SYNE1 methylation in colorectal cancer was not closely correlated to its clinicopathological characteristics（P〉0. 05）. Conclusion SYNE1 methylation is an early gene event of carcinogenesis for colorectal cancer. SYNE1 is a candidate biomarker in early diagnosis of colorectal cancer.